Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.
|Articles|November 1, 2006
Ramping up funding for cancer research
John E. Niederhuber, M.D., named this summer by President Bush to become the 13th director of the National Cancer Institute (NCI), faces the difficult task of balancing pressures to reduce costs with the need to expand the nation's investment in cancer research.
Advertisement
Advertisement
Related to this article
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Dermatology Times is looking back on the top stories in dermatology from the month of September.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
From emerging therapies to earlier intervention and psychosocial support, Dermatology Times looks back at key alopecia areata developments in 2026.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis
2
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
3
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
4
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
5